Your browser doesn't support javascript.
loading
Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review.
Dimou, Maria; Bitsani, Aikaterini; Bethge, Wolfgang; Panayiotidis, Panayiotis; Vassilakopoulos, Theodoros P.
Afiliación
  • Dimou M; First Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece; msdimou@gmail.com.
  • Bitsani A; First Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
  • Bethge W; Department Hematology & Oncology Internal Medicine II, University Hospital Tuebingen, Tuebingen, Germany.
  • Panayiotidis P; First Internal Medicine Department, Propaedeutic, Hematology Clinical Trial Unit, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
  • Vassilakopoulos TP; Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
In Vivo ; 35(6): 3401-3406, 2021.
Article en En | MEDLINE | ID: mdl-34697175
BACKGROUND: Failure after CD19-directed chimeric antigen receptor (CAR) T-cell therapy for patients with large B-cell B non-Hodgkin lymphoma, especially when it happens early, is an emerging clinical problem. There are no specific recommendations and therefore treatment of these patients remains empiricaI. Immune checkpoint inhibitors are becoming a therapeutic option for these patients. CASE REPORT: We present a case of a primary mediastinal large B-cell lymphoma who experienced relapse 3.5 months after axicabtagene-ciloleucel therapy and received pembrolizumab. After four cycles of pembrolizumab, complete metabolic response was confirmed. Treatment was discontinued after the sixth cycle due to immune checkpoint inhibitor-related pneumonitis. The disease remains in remission 8 months after the last pembrolizumab dose. We propose mechanisms of action and optimal duration of pembrolizumab treatment in this setting. Finally, we review the existing literature on the sequential administration of CD19-directed CAR T-cell therapy and immune checkpoint inhibitors. CONCLUSION: Immune checkpoint inhibitors are a promising treatment option for patients after failure of CD19-directed CAR-T cell therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B Grandes Difuso / Anticuerpos Monoclonales Humanizados / Recurrencia Local de Neoplasia Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: In Vivo Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B Grandes Difuso / Anticuerpos Monoclonales Humanizados / Recurrencia Local de Neoplasia Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: In Vivo Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article Pais de publicación: Grecia